FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Representatives of the Centers for Disease Control and Prevention discuss the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).

This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).

To download the podcast, click here.